...and final close of its series D, bringing its total to €39.7 million ($44.4 million). Itochu Corp....

...path to near term resubmission,” with a potential 2H17 action date. The companies said that Itochu Corp....

...response letter for the candidate. Scilex's investors include the Itochu Chemical Frontier Corp. subsidiary of Itochu Corp....

...Itochu’s Itochu Chemical Frontier Corp. company made an undisclosed investment in neurology company Scilex. The investment...
...further details, and Itochu could not be reached. Scilex Pharmaceuticals Inc. , West Chester, Pa. Itochu Corp....

...trials could take 24-30 months to conduct, IART said. Century Medical is a subsidiary of Itochu Corp....

...create safer oral therapies addressing various GI disorders 2004 $55M series D, 2004 ATEL Ventures; Itochu...

...in Japan, according to CEO Steve Engen. JapanBridge was the brainchild of MPM Capital and Itochu Corp....
...Koji Shinozaki, who co-founded JapanBridge as VP of corporate development and was formerly leader of Itochu's...
...series A1 seed money at its formation, including $1.05 million from MPM and $250,000 from Itochu...

...immunogenicity screening technology in Japan. Financial terms were not disclosed. AlgoNomics N.V. , Ghent, Belgium Itochu Corp....

...will allow it to quickly raise cash. Returning LPs, such as GE Healthcare Financial Services, Itochu...

...including neurology company Memory (MEMY) and Australian cancer play Peplin (ASX:PEP). Investors included GE Healthcare; Itochu...